Zacks: Analysts Expect Iterum Therapeutics PLC (ITRM) Will Announce Earnings of -$1.96 Per Share

Wall Street analysts predict that Iterum Therapeutics PLC (NASDAQ:ITRM) will report earnings per share of ($1.96) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Iterum Therapeutics’ earnings. The firm is scheduled to report its next earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Iterum Therapeutics will report full year earnings of ($11.29) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($5.52) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Iterum Therapeutics.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($2.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by ($0.78). The business had revenue of $0.19 million during the quarter.

ITRM has been the topic of several recent analyst reports. Needham & Company LLC initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued a “buy” rating and a $20.00 price target on the stock. Leerink Swann initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued an “outperform” rating and a $18.00 price target on the stock. Guggenheim initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Royal Bank of Canada initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued an “outperform” rating and a $24.00 price target on the stock.

Shares of ITRM opened at $8.69 on Friday. Iterum Therapeutics has a 52-week low of $8.09 and a 52-week high of $13.00. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.12.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frazier Management LLC bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $16,414,000. Granahan Investment Management Inc. MA bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $2,570,000. Millennium Management LLC bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $1,867,000. Tiverton Asset Management LLC bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $1,529,000. Finally, Neuburgh Advisers LLC bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $675,000. Hedge funds and other institutional investors own 47.63% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Article: What is the NASDAQ?

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply